Surrozen to Present at Upcoming Healthcare Investor Conferences
06 nov. 2024 16h30 HE
|
Surrozen, Inc.
Surrozen to Present at Upcoming Healthcare Investor Conferences in November 2024
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
06 nov. 2024 09h00 HE
|
Surrozen, Inc.
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
04 nov. 2024 08h30 HE
|
Surrozen, Inc.
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary FIbrosis
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
24 sept. 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
12 août 2024 16h05 HE
|
Surrozen, Inc.
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
12 juin 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Publishes Study in eLife Demonstrating the Promise of the SWEETS Platform, a Unique TPD Technology, to Further Enhance Wnt Signaling
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
10 juin 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 at the 2024 European Association for the Study of the Liver (EASL) in Milan
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
04 juin 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
09 mai 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024
Surrozen Provides First Quarter 2024 Financial Results and Business Update
08 mai 2024 16h05 HE
|
Surrozen, Inc.
Surrozen Provides First Quarter 2024 Financial Results and Business Update